Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 8,253 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Age Clear all
Not yet recruiting Not applicable Interventional

E-cigarette Social Media Marketing and Its Perceptions by Youth

NCT07694739
View directory record Official record
Conditions
Vaping
Interventions
Exposure to Influencer Age and Context Variations in E-Cigarette Marketing
Other
Lead sponsor
University of Southern California
Other
Eligibility
14 Years to 17 Years
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 26, 2026, 1:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

NCT06931275
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
EMR-based BPA model, Placebo (EMR-based without BPA model)
Other · Behavioral
Lead sponsor
T1D Exchange, United States
Other
Eligibility
2 Years to 95 Years
Enrollment
1,178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 26, 2026, 1:02 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes

NCT03356457
View directory record Official record
Conditions
Hyperglycaemia (Diabetic)
Interventions
Dichloroacetate, Placebo oral capsule
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 26, 2026, 1:02 PM EDT
Completed Not applicable Interventional Results available

Treating Sleep Problems in VA Adult Day Health Care

NCT01259401
View directory record Official record
Conditions
Insomnia, Sleep Disorders
Interventions
Sleep Intervention Program, Sleep Education control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Sepulveda, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 26, 2026, 1:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Brief MI Intervention in the ED to Increase Child Passenger Restraint Use

NCT02496481
View directory record Official record
Conditions
Child Restraint Systems, Seat Belts
Interventions
Motivational Interviewing, Tailored brochure
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan • Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 26, 2026, 1:02 PM EDT
Not listed Phase 2Phase 3 Interventional

An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III

NCT06614894
View directory record Official record
Conditions
Sanfilippo Syndrome, MPS3
Interventions
Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day
Drug
Lead sponsor
Ozlem Goker-Alpan
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 26, 2026, 1:02 PM EDT
Active, not recruiting Phase 3 Interventional

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
11
States / cities
Bakersfield, California • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 26, 2026, 1:02 PM EDT
Terminated Phase 3 Interventional Results available

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

NCT04802837
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ridinilazole, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
12 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 26, 2026, 1:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Auditory EEG and Behavioral Assessments in Individuals With Rett Syndrome

NCT07569445
View directory record Official record
Conditions
Rett Syndrome
Interventions
Electroencephalogram (EEG) Recording
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
2 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 26, 2026, 1:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET Scan of Brain Metabolism in Relation to Age and Disease

NCT00001972
View directory record Official record
Conditions
Alzheimer's Disease, Brain Neoplasm, Niemann Pick Disease
Interventions
15 O Water
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 1:02 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Brain Blood Vessel Responses to Changes in Blood Flow

NCT06629077
View directory record Official record
Conditions
Magnetic Resonance Imaging, Cerebrovascular Circulation
Interventions
MRI, Prazosin, Placebo
Device · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 69 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 26, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Twice Weekly Steroids and Exercise as Therapy for DMD

NCT04322357
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
Prednisone, Exercise Training on standard steroid regimen, Exercise training on twice-weekly steroids
Drug · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 9 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 26, 2026, 1:02 PM EDT
Completed Not applicable Interventional

Computer-Based Behavior Change Guide in Increasing Physical Activity in Patients With Prostate Cancer Who Have Received Androgen Deprivation Therapy

NCT02869412
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Computer-Assisted Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 26, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

NCT00262028
View directory record Official record
Conditions
Prevention of Meningococcal Disease
Interventions
MenACWY-CRM Vaccine, MenACWY-PS Vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
12 Months to 10 Years
Enrollment
910 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 26, 2026, 1:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Modulation of Neuroinflammation in Age-Related Memory Disorders

NCT03723694
View directory record Official record
Conditions
Memory Loss, Inflammation
Interventions
650 mg of Cocoapro flavanols, 0 mg of Cocoapro flavanols
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 69 Years
Enrollment
259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 26, 2026, 1:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner

NCT01832883
View directory record Official record
Conditions
Amblyopia, Strabismus
Interventions
Pediatric Vision Scanner
Device
Lead sponsor
Rebiscan, Inc.
Industry
Eligibility
3 Years to 8 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 26, 2026, 1:02 PM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

NCT02736656
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 18 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
16
States / cities
Little Rock, Arkansas • Long Beach, California • Colorado Springs, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 26, 2026, 1:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Platelet Volunteers, Longitudinal and Multi-omic Study

NCT07137429
View directory record Official record
Conditions
Thrombosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2041
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 26, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

NCT00129129
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 26, 2026, 1:02 PM EDT
Terminated Phase 2 Interventional Results available

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

NCT00939653
View directory record Official record
Conditions
Relapsed Acute Myelogenous Leukemia
Interventions
Clofarabine, Etoposide, Cyclophosphamide, Filgrastim, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 26, 2026, 1:02 PM EDT
Terminated Phase 2 Interventional Results available

Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)

NCT00904345
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab, 50-60 Gy and 70 Gy
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
70 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 26, 2026, 1:02 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study

NCT05667701
View directory record Official record
Conditions
Wheezing, Asthma in Children
Interventions
Soy isoflavone, matching placebo
Drug
Lead sponsor
Rajesh Kumar
Other
Eligibility
2 Months to 12 Months
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 26, 2026, 1:02 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.

NCT06692712
View directory record Official record
Conditions
Hereditary Spastic Paraplegia Type 50
Interventions
MELPIDA
Genetic
Lead sponsor
Elpida Therapeutics SPC
Industry
Eligibility
4 Months to 72 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 26, 2026, 1:02 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

NCT01049022
View directory record Official record
Conditions
Infections
Interventions
Moxifloxacin (Avelox, BAY12-8039)
Drug
Lead sponsor
Bayer
Industry
Eligibility
3 Months to 14 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 26, 2026, 1:02 PM EDT